Anocca

Anocca is a Swedish biotechnology company specializing in the development of T-cell receptor-engineered T cell (TCR-T) therapies for the treatment of solid tumors. Founded in 2014 and headquartered in Södertälje, Sweden, Anocca utilizes a proprietary technology platform that enables high-precision and standardized analysis of T-cell biology. This platform allows for the rapid identification and validation of new disease antigens, as well as the identification, characterization, and engineering of T-cell receptors (TCRs) in an industrialized process.

The company's approach involves systematically recreating and manipulating T-cell immunity to identify the most effective targets and TCRs for each tumor type. Anocca has built validated asset franchises against cancer targets including KRAS, PRAME, and MAGE, with more than 40 preclinical assets in its pipeline as of January 2024. Its lead franchise of TCR-T therapies targets KRAS driver mutations, which are responsible for extremely aggressive forms of cancer.

Anocca's manufacturing process utilizes a next-generation autologous approach that leverages non-viral gene editing to insert therapeutic TCRs into a patient's own T cells. In January 2024, the company received a certificate of good manufacturing practice (GMP) compliance from the Swedish Medical Product Agency for its in-house cell therapy manufacturing facility, which is reported to be the largest facility in the Nordics for clinical supply of cell therapies.

In addition to its work in oncology, Anocca is exploring the potential use of its technology in developing prophylactic vaccines and treatments for autoimmune diseases. The company employs approximately 90-100 people and operates advanced research and development infrastructure, including in-house clinical manufacturing and process development facilities.